PDS Biotech to Present at the LD Micro Main Event XV

FLORHAM PARK, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that its management will present at the LD Micro Main Event XV conference being held at the Luxe Sunset Boulevard Hotel in Beverly Hills, California, on October 25-27, 2022.

LD Micro Main Event XV Presentation Date: Wednesday, October 26, 2022Time: 4:30 PM PDTVirtual viewers: Livestream

About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-positive cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Investor Contacts: Rich Cockrell CG Capital Phone: +1 (404) 736-3838 Email: [email protected]

Media Contacts: Dave Schemelia Tiberend Strategic Advisors Inc.Phone: +1 (609) 468-9325 Email: [email protected]

Bill Borden Tiberend Strategic Advisors Inc.Phone: +1 (732) 910-1620 Email: [email protected]

Source: PDS Biotechnology Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• The Frontier Goes Public — and the Whole Sector Comes With It
• From Nokia to NeOnc: The Stocks Dominating Screens as Volume Spikes
• WLFI Price Prediction: Can Pepeto Deliver What World Liberty Financial Cannot?